Applied Biosystems and Asuragen Collaborate with the Critical Path Institute to Improve Drug Toxicity Screening
News Nov 07, 2008
Applied Biosystems Inc. and Asuragen, Inc. are collaborating with the Critical Path Institute’s Predictive Safety Testing Consortium to develop a predictive gene signature panel that will allow pharmaceutical companies to screen potential therapeutics for toxic effects in pre-clinical samples.
As part of the collaboration, Critical Path Institute (C-Path), Applied Biosystems, and Asuragen, Inc. will partner to develop a panel of assays with gene targets determined to be associated with carcinogenicity in laboratory rats, a common model organism for pharmaceutical testing.
The collaborators will also use the Applied Biosystems assays to determine and differentiate effects that are genotoxic from non-genotoxic modes of action to assist in risk assessment. The new biomarker panel will be based on Applied Biosystems’ TaqMan® Gene Signature Array and real-time PCR technology.
“The development of robust turnkey assays to speed development of therapeutics for patients is one of the fundamental goals of the Critical Path Initiative, for which we believe we can make a difference working with partners such as Applied Biosystems and Asuragen,” said William B. Mattes, Ph.D., director of C-Path’s Predictive Safety Testing Consortium. “We expect this collaboration will facilitate broader utility of genomic biomarkers of toxicity across the industry in order to enable the early prediction and mechanistic understanding of potential carcinogens in pre-clinical research.”
The Predictive Safety Testing Consortium (PSTC) was established by C-Path to bring together major pharmaceutical companies to work in collaboration with C-Path and in coordination with the FDA. Its objective is to enable the exchange of knowledge and resources to speed drug development and improve drug safety. The Consortium currently has 16 members. Scientists from the FDA and its European counterpart, the European Medicines Agency, as well as academic experts also participate as advisors.
Increasingly, researchers are using Applied Biosystems comprehensive line of RNA analysis tools based on gold-standard TaqMan chemistry for the development of potential biomarkers. For this project, Applied Biosystems is providing PSTC scientists with its TaqMan Gene Signature Arrays. PSTC scientists will use this collection of RNA expression assays to develop a biomarker panel for use in screening potential therapeutics for carcinogenic effects in pre-clinical samples.
“Biomarkers that allow early prediction of toxicity will enable pharmaceutical companies to make better compound selection decisions and facilitate the early initiation of risk assessment work that would otherwise delay bringing important medicines to market,” said Peter Dansky, president of Applied Biosystems’ functional analysis division. “We are committed to continue expanding our menu of TaqMan Arrays for applications requiring a robust and highly-sensitive detection system in an easy-to-use and standardized format, such as in high-throughput drug screening.”
The development of tools that improve drug toxicity screening involves the generation and analysis of vast amounts of molecular data. Asuragen is contributing crucial laboratory services, pharmacogenomic expertise, and bioinformatics capabilities for the Predictive Safety Testing Consortium project.
Have you ever been stressed out by the idea of doing math or statistics problems? You’re not alone. A new study has used a questionnaire and an analytical technique called "network science" to determine precisely what factors contribute to this kind of statistics anxiety among psychology majors.
Anxiety and depression are surprisingly common among young children. But it can be hard to detect these conditions, known as “internalizing disorders,” because the symptoms are so inward-facing that parents, teachers and doctors often fail to notice them. Now, researchers have developed a tool that could help screen children for internalizing disorders to catch them early enough to be treated.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019